Keywords: Genentech, Biogen Idec, Roche, Ocrelizumab, Rheumatoid arthritis, Research

Genentech/Biogen’s ocrelizumab meets primary endpoints in first Ph III Trial in RA

Article | 14 December 2009

Print This

US biotechnology major Genentech, a wholly owned subsidiary of Switzerland’s Roche, and Biogen Idec have revealed results form a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in